Blue Owl Capital Holdings LP holds a concentrated book of 71 stocks worth $658.0M as of Q2 2026 (disclosed Aug 11, 2026, a ~42-day 13F lag). This quarter they opened Space Exploration Techn Corp and trimmed Aktis Oncology Inc. Their largest long position is Space Exploration Techn Corp at 36% of the equity book. They also disclosed $6.5M in call options (bullish), shown separately below and excluded from the equity book. Cloning the disclosed picks since 2025 would be +28% (+17.7%/yr). That is a simulation of the disclosed long book, not audited returns.
Following at the filing date actually beat the quarter-end book by 15.8 points over this window.
Growth of $10,000 cloning Blue Owl Capital Holdings LP's disclosed long 13F book, rebalanced on each filing date (so it reflects each quarter's actual reporting lag, ~42 days for the latest filing, with no look-ahead), total-return basis (dividends reinvested), derived from end-of-day prices. “Their reported book” values the same picks from quarter-end, before they were public. S&P 500 is SPY total return over the same window. Excludes shorts, cash, options and non-13F holdings. Not investment advice.
Top-heavy: concentrated book
Share of the disclosed book in its largest positions. A higher top-5 share means a more concentrated, higher-conviction portfolio.
54% mapped to company sectors
Direct operating-company sectors from our SIC-based security master. ETF/fund and unclassified holdings stay visible separately; this is not ETF look-through exposure.
Estimated $ traded · quarter-end prices, no cost basis
Other tracked managers holding the same core names as Blue Owl Capital Holdings LP
| Manager / fund | Shared names | Their $ in those |
|---|---|---|
| UBS Group AG | 61 / 71 | $2.1B |
| GOLDMAN SACHS GROUP INC | 54 / 71 | $4.7B |
| MORGAN STANLEY | 51 / 71 | $5.4B |
| GEODE CAPITAL MANAGEMENT, LLC | 50 / 71 | $9.7B |
| JPMORGAN CHASE & CO | 48 / 71 | $5.5B |
| BlackRock, Inc. | 46 / 71 | $17.1B |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 46 / 71 | $218.2M |
| BANK OF AMERICA CORP /DE/ | 45 / 71 | $4.7B |
Ranked by how many of Blue Owl Capital Holdings LP's top 71 disclosed names each fund also holds: a cross-fund conviction signal from the latest 13F of every tracked manager.
Bars show each stock's share of the portfolio. Click a row for its position history.
| # | Security | Value | Shares | % Port | Last move | History |
|---|---|---|---|---|---|---|
| 1 | Space Exploration Techn Corp CLASS A COM STK | $239.0M | 1.40M | 36.3% | ▲New New position | |
| 2 | Aktis Oncology Inc COM | $99.0M | 3.07M | 15.0% | ▼−2.9% Reduced · −91K sh | |
| 3 | Cullinan Therapeutics Inc COM | $28.0M | 1.54M | 4.3% | ▼−19% Reduced · −370K sh | |
| 4 | Larimar Therapeutics Inc COM | $27.9M | 9.16M | 4.2% | ▲+29% Added · +2.0M sh | |
| 5 | Nuveen Churchill Direct Lend COM SHS | $26.6M | 2.14M | 4.0% | —Held | |
| 6 | Maplight Therapeutics Inc COM | $26.2M | 729.9K | 4.0% | ▼−27% Reduced · −276K sh | |
| 7 | Capital One Finl Corp COM | $24.0M | 119.8K | 3.7% | ▲New New position | |
| 8 | Blue Owl Capital Corporation COM | $22.2M | 2.05M | 3.4% | —Held | |
| 9 | Deep Fission Inc COM | $14.7M | 1.33M | 2.2% | ▲New New position | |
| 10 | Dell Technologies Inc CL C | $14.2M | 33.0K | 2.2% | ▲+137% Added · +19K sh | |
| 11 | Holley Inc COM | $11.2M | 4.38M | 1.7% | ▲+3.3% Added · +140K sh | |
| 12 | Eyepoint Inc COM NEW | $10.9M | 762.6K | 1.7% | ▼−16% Reduced · −150K sh | |
| 13 | Sagimet Biosciences Inc COM SER A | $9.7M | 1.26M | 1.5% | ▲+278% Added · +927K sh | |
| 14 | Corvus Pharmaceuticals Inc COM | $9.1M | 608.6K | 1.4% | ▲+12% Added · +64K sh | |
| 15 | Artiva Biotherapeutics Inc COM | $8.5M | 874.5K | 1.3% | ▲New New position | |
| 16 | Compass Therapeutics Inc COM | $7.9M | 3.62M | 1.2% | ▲+23% Added · +683K sh | |
| 17 | Conduent Inc COM | $7.4M | 5.04M | 1.1% | —Held | |
| 18 | Rhythm Pharmaceuticals Inc COM | $6.8M | 61.5K | 1.0% | —Held | |
| 19 | Compass Pathways PLC SPONSORED ADS | $6.4M | 450.0K | 1.0% | ▲New New position | |
| 20 | Ultragenyx Pharmaceutical In COM | $6.1M | 182.6K | 0.9% | ▼−40% Reduced · −120K sh | |
| 21 | Palvella Therapeutics Inc Ne COM | $5.5M | 36.3K | 0.8% | ▲+16% Added · +5K sh | |
| 22 | Imagenebio Inc COM | $5.4M | 917.7K | 0.8% | ▼−4.3% Reduced · −42K sh | |
| 23 | Viridian Therapeutics Inc COM | $4.8M | 260.0K | 0.7% | ▲New New position | |
| 24 | Immix Biopharma Inc COM | $4.5M | 437.6K | 0.7% | ▼−20% Reduced · −110K sh | |
| 25 | Oric Pharmaceuticals Inc COM | $4.3M | 400.0K | 0.7% | ▲+167% Added · +250K sh | |
| 26 | Lenz Therapeutics Inc COM | $4.3M | 756.7K | 0.7% | ▲+49% Added · +250K sh | |
| 27 | Aquestive Therapeutics Inc COM | $3.9M | 942.9K | 0.6% | ▼−30% Reduced · −405K sh | |
| 28 | Starwood Ppty TR Inc COM | $3.2M | 196.4K | 0.5% | ▲+24% Added · +38K sh | |
| 29 | Evommune Inc COM SHS | $2.4M | 180.0K | 0.4% | ▲+80% Added · +80K sh | |
| 30 | Eledon Pharmaceuticals Inc COM | $2.2M | 566.5K | 0.3% | ▼−60% Reduced · −853K sh | |
| 31 | Cabaletta Bio Inc COM | $2.2M | 714.7K | 0.3% | ▲New New position | |
| 32 | Chime Finl Inc COM SHS CL A | $1.8M | 89.9K | 0.3% | ▲New New position | |
| 33 | Context Therapeutics Inc COM | $1.6M | 2.93M | 0.2% | ▼−42% Reduced · −2.2M sh | |
| 34 | WW Intl Inc COM | $1.3M | 84.4K | 0.2% | ▼−12% Reduced · −11K sh | |
| 35 | Marker Therapeutics Inc COM NEW | $815K | 554.3K | 0.1% | —Held | |
| 36 | Adc Therapeutics Sa SHS | $785K | 733.6K | 0.1% | —Held | |
| 37 | Cybin Inc COM NEW | $396K | 59.9K | 0.1% | ▲New New position | |
| 38 | Fold Hldgs Inc COM CL A | $385K | 856.6K | 0.1% | —Held | |
| 39 | Niocorp Devs Ltd *W EXP 03/17/202 | $381K | 268.3K | 0.1% | ▼−16% Reduced · −52K sh | |
| 40 | Rezolve AI PLC *W EXP 08/15/202 | $214K | 235.1K | 0.0% | —Held | |
| 41 | Brand Engagement Network Inc *W EXP 03/14/202 | $204K | 1.45M | 0.0% | ▼−13% Reduced · −213K sh | |
| 42 | Piper Sandler Companies COM NEW | $176K | 2.4K | 0.0% | —Held | |
| 43 | Engene Therapeutics Inc *W EXP 10/31/202 | $148K | 511.2K | 0.0% | ▲New New position | |
| 44 | Celcuity Inc COM | $131K | 1.2K | 0.0% | ▲New New position | |
| 45 | Stablecoinx Inc *W EXP 06/25/203 | $103K | 250.0K | 0.0% | ▲New New position | |
| 46 | Energy Transfer L P COM UT LTD PTN | $102K | 5.3K | 0.0% | —Held | |
| 47 | Caris Life Sciences Inc COM | $84K | 4.7K | 0.0% | —Held | |
| 48 | Vodafone Group PLC SPONSORED ADR | $71K | 5.4K | 0.0% | ▲New New position | |
| 49 | Dave Inc *W EXP 01/05/202 | $68K | 28.8K | 0.0% | —Held | |
| 50 | Murano Global Invt PLC SHS | $63K | 261.9K | 0.0% | ▲New New position |
The public view is the crawlable proof. The same sourced dataset is available through REST and MCP for agents, research scripts, and back-office tools.
This fund page is the Follow view. The Build view lets your agent pull holdings, quarter changes, overlap, and source filings through API or MCP.
curl -H "Authorization: Bearer YOUR_API_KEY" \ "https://arkolith.com/api/v1/funds/1858703/holdings"
Use Arkolith to show Blue Owl Capital Holdings LP's latest holdings, largest changes, and filing provenance.
Put / call positions from the 13F — totals include every disclosed option leg
| Type | Underlying | Notional value | Underlying shares |
|---|---|---|---|
| CALL · bullish | COMPASS PATHWAYS PLC | $5.2M | 1.7M |
| CALL · bullish | ERASCA INC | $795K | 100K |
| CALL · bullish | ELEDON PHARMACEUTICALS INC | $285K | 200K |
| CALL · bullish | LARIMAR THERAPEUTICS INC | $146K | 729K |
| CALL · bullish | COMPASS THERAPEUTICS INC | $106K | 304K |
13F filers disclose option positions at the market value of the underlying the contracts reference, not the premium paid. A put is a bearish bet (it gains if the stock falls); a call is bullish. “Underlying shares” is the share count the contracts control, not a share holding. These legs are excluded from the equity book, weighting, concentration and sector figures above.
As-of date vs the date the SEC received each filing
| Quarter | As of | Filed | Positions | Value | Form |
|---|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | Aug 11, 2026 | 76 | $664.5M | 13F-HR |
| Q1 2026 | Mar 31, 2026 | May 14, 2026 | 76 | $372.2M | 13F-HR |
| Q4 2025 | Dec 31, 2025 | Feb 20, 2026 | 82 | $324.0M | 13F-HR/A |
| Q3 2025 | Sep 30, 2025 | Nov 12, 2025 | 75 | $322.1M | 13F-HR |
| Q2 2025 | Jun 30, 2025 | Aug 11, 2025 | 73 | $309.9M | 13F-HR |
| Q1 2025 | Mar 31, 2025 | May 15, 2025 | 74 | $310.1M | 13F-HR |
| Q4 2024 | Dec 31, 2024 | Feb 14, 2025 | 80 | $434.0M | 13F-HR |
Holdings from SEC EDGAR 13F-HR filings, updated quarterly, filed up to 45 days after quarter-end. Public domain. The book and weighting are long equity only; disclosed put/call options are listed separately and excluded from those totals. The performance line is a simulation of the disclosed long book, not an audited return.